Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Shanghai Fosun Pharmaceutical Industrial Development obtained registration approval for Deferasirox tablets and granules from China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The drugs are indicated for the treatment of chronic iron overload due to blood transfusions in patients above two years of age and in patients over 10 with non-transfusion-dependent thalassemia syndromes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.